September 6, 2018 / 2:46 AM / in 2 months

BRIEF-Novartis Says To Divest Sandoz U.S. Dermatology Business And Generic U.S. Oral Solids Portfolio To Aurobindo

Sept 5 (Reuters) - Novartis AG:

* NOVARTIS TO DIVEST SANDOZ US DERMATOLOGY BUSINESS AND GENERIC US ORAL SOLIDS PORTFOLIO TO AUROBINDO

* TO FOCUS SANDOZ DIVISION IN US ON HIGHER GROWTH AREAS AND TO SELL SELECTED PORTIONS OF SANDOZ US PORTFOLIO TO AUROBINDO PHARMA USA

* AGREEMENT COMPRISES SANDOZ US GENERIC ORAL SOLIDS AND SANDOZ US DERMATOLOGY BUSINESSES

* AGREED TO SELL SELECTED PORTIONS OF SANDOZ US PORTFOLIO TO AUROBINDO PHARMA USA FOR $0.9 BILLION OF CASH PLUS $0.1 BILLION OF POTENTIAL EARN-OUTS

* SANDOZ US PORTFOLIOS TO BE SOLD TO AUROBINDO INCLUDE APPROXIMATELY 300 PRODUCTS, AS WELL AS ADDITIONAL DEVELOPMENT PROJECTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below